| Ytd | 73.86% | |
| 1y | -2.14% |
| Open | 7.27 | Prev Close | 7.30 | Low | 6.75 | High | 7.28 | Mkt Cap | 204.05M |
| Vol | 51.22K | Avg Vol | 43.41K | EPS | -0.13 | P/E | N/A | Forward P/E | N/A |
| Beta | N/A | Short Ratio | N/A | Inst. Own | N/A | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 5.02 | 200-d Avg | 4.25 | 1yr Est | 0.00 |
TTRX News
92.6% of GX-03-treated subjects achieved a 50% reduction in eczema severity in 4 weeks (EASI-50); 70
Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.03) per share which missed the anal
D. Boral Capital analyst Jason Kolbert maintains Turn Therapeutics (NASDAQ:TTRX) with a Buy and m
Phase 2 trial of GX-03 for moderate-severe atopic dermatitis on track to complete both interim analy
D. Boral Capital analyst Jason Kolbert initiates coverage on Turn Therapeutics (NASDAQ:TTRX) with
Turn Therapeutics (NASDAQ:TTRX) ("Turn" or the "Company"), a clinical-stage biotechn
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock
Stock futures mixed, investor focus on PepsiCo, Costco, and Delta earnings. Turn Therapeutics surges
Turn Therapeutics' shares surged 134% in after-hours trading following its Nasdaq debut, despite